• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    1/30/25 4:30:30 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    false 0001737995 0001737995 2025-01-28 2025-01-28 0001737995 STSS:CommonStock0.0001ParValueMember 2025-01-28 2025-01-28 0001737995 STSS:CommonStockPurchaseWarrantsMember 2025-01-28 2025-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): January 28, 2025

     

    Sharps Technology, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada

    (State or Other Jurisdiction of Incorporation)

     

    001-41355   82-3751728

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    105 Maxess Road, Melville, New York 11747

    (Address of Principal Executive Offices)

     

    (631) 574 -4436

    (Registrant’s Telephone Number, Including Area Code)

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   STSS   NASDAQ Capital Market
    Common Stock Purchase Warrants   STSSW   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On January 28, 2025, pursuant to the registration statement on Form S-1, as amended (File No. 333-284237) (the “Registration Statement”), Sharps Technology, Inc., a Nevada corporation (the “Company”) consummated a public offering (the “Offering”) of an aggregate of (i) 14,285,714 units (the “Units) at a public offering price per Unit of $1.40 with each Unit consisting of one share of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), one Series A Warrant (the “Series A Warrant”) to purchase one share of Common Stock at an exercise price of $1.750 per share and one Series B Warrant to purchase one share of Common Stock at an exercise price of $1.750 (the “Series B Warrant” and, together with Series A Warrant, the “Warrants”); and (ii) 10,833,500 pre-funded units (the “Pre-Funded Units”) at a public offering price of $1.3999 per Pre-Funded Unit, with each Pre-Funded Unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) exercisable for one share of Common Stock at an exercise price of $0.0001 per share, one Series A Warrant and one Series B Warrant. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

     

    The Series A Warrants will be exercisable from issuance and will expire five (5) years after the Warrant Stockholder Approval Date and the Series B Warrants will be exercisable from issuance and will expire two and one-half (2.5) years after the Warrant Stockholder Approval Date (the “Warrant Stockholder Approval Date”).

     

    The offering closed on January 29, 2025. The net proceeds to the Company from the Offering were approximately $18,200,000, after deducting underwriter fees and the payment of other estimated offering expenses associated with the offering that are payable by the Company. The Company intends to use the net proceeds from the offering for repayment of debt, working capital and other general corporate purposes.

     

    Aegis Capital Corp. served as the underwriter in the offering, pursuant to the terms of an Underwriting Agreement, and received seven percent (7%) of the gross proceeds of the offering, a one percent (1%) non-accountable allowance and reimbursement of the legal fees of its counsel.

     

    The Units and Pre-Funded Units were offered by the Company pursuant to a Registration Statement on Form S-1, as amended (File No. 333-284237), which was originally filed with the Securities and Exchange Commission (“the SEC”) on January 10, 2025, and declared effective by the SEC on January 27, 2025. The final prospectus relating to the offering was filed with the SEC on January 29, 2025.

     

    The foregoing summary of the terms of the Pre-Funded Warrant, Series A Warrant, Series B Warrant, and the Underwriting Agreement are subject to, and qualified in their entirety by reference to the full text of such agreements, copies of which are filed as Exhibits 4.1, 4.2, 4.3, and 10.1 respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits

     

    Exhibit No.   Description
    4.1   Form of Pre-Funded Warrant
    4.2   Form of Series A Warrant
    4.3   Form of Series B Warrant
    10.1   Underwriting Agreement between the Company and Aegis Capital Corp., dated January 28, 2025
    99.1   Press Release issued by the Company on January 28, 2025
    99.2   Press Release issued by the Company on January 29, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 30, 2025

     

    SHARPS TECHNOLOGY, INC.  
       
    /s/ Robert Hayes  
    Robert Hayes  
    Chief Executive Officer  

     

     

     

    Get the next $STSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Falconx Holdings Ltd claimed ownership of 769,230 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:10:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Large owner Saba Capital Management, L.P. sold $86,371 worth of shares (37,182 units at $2.32) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    1/20/26 5:55:14 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sharps Technology and BitGo Announce Collaboration to Advance Solana Treasury Strategy

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS), a medical device company with a Solana (SOL) digital asset treasury strategy, and BitGo Bank & Trust, National Association ("BitGo"), the digital asset infrastructure company, today announced a strategic collaboration under which STSS will expand and further institutionalize its Solana treasury strategy through BitGo's services. As part of this arrangement, STSS intends to utilize BitGo's institutional-grade qualified custody through its OCC regulated entity, BitGo Bank & Trust, National Association. In addition, STSS intends to leverage BitGo's Solana staking validator to earn com

    2/5/26 7:00:00 AM ET
    $BTGO
    $STSS
    Finance: Consumer Services
    Finance
    Medical/Dental Instruments
    Health Care

    Sharps Technology Reports Strong Solana Staking Income

    NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company"), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury and recent operational highlights. Treasury Updates Staking: Since inception, STSS's validator partners have generated ~7% gross annual percentage yield (APY) before fees, outperforming the Solana network average. Nearly all of the Company's SOL holdings are currently staked.Balance Sheet: STSS continues to maintain sufficient operating capital and has no corporate debt. Recent Operational Highlights In January, STSS announced a lock-up agreement with its Strategic Advi

    1/26/26 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference Carmel LLP ("SRFC") reported that in 2025 it advised on over 170 announced transactions, with the total value of these transactions exceeding $14 billion, far surpassing the firm's strong performance in 2024. The transactions, on behalf of various market participants, such as issuers, underwriters and investors, included initial public offerings, secondary public offerings, registered direct offerings, private placements, mergers, acquisitions and cryptocurrency transactions. In October of 2025, for the fifth consecutive quarter, SRFC was ranked first in the nation for issuer counsel among securities law firms in Placement

    1/20/26 8:00:00 AM ET
    $EMIS
    $NCRA
    $SOUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Farming/Seeds/Milling
    Consumer Staples

    $STSS
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Sharps Technology Inc.

    SCHEDULE 13D - Sharps Technology Inc. (0001737995) (Subject)

    2/13/26 4:15:01 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Sharps Technology Inc.

    EFFECT - Sharps Technology Inc. (0001737995) (Filer)

    2/2/26 12:15:19 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.

    SCHEDULE 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    1/23/26 6:09:54 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

    NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

    2/16/24 2:42:54 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

    Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

    7/12/23 8:33:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Justin Page as Vice President of Technical Operations

    NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

    2/9/23 9:21:23 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Financials

    Live finance-specific insights

    View All

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

    6/7/24 9:00:00 AM ET
    $SNGX
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

    9/29/23 9:00:00 AM ET
    $AREC
    $RVPH
    $STSS
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    10/9/24 9:01:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sharps Technology Inc.

    SC 13G - Sharps Technology Inc. (0001737995) (Subject)

    2/14/24 11:14:11 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care